Document:

mblc_ex108.htm

EXHIBIT 10.8
  
 MILLENNIUM BLOCKCHAIN INC.
  
 COMMON STOCK PURCHASE AGREEMENT
  
 THIS COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of July 31, 2018 (the “Execution Date”), by and between Millennium Blockchain Inc., a Nevada corporation (the “Company”), and Robot Cache, S.L., a Spanish sociedad limitada (the “Investor”).
  
 RECITALS
  
 WHEREAS, pursuant to terms and subject to the conditions set forth in this Agreement, the Company desires to sell to the Investor, and the Investor desires to purchase from the Company, shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), as well as warrants to purchase Common Stock;
  
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
  
 SECTION 1
  
 Purchase and Sale of Shares
  
 1.1 Sale of Shares. Subject to the terms and conditions hereof, the Company will issue and sell to the Investor, and the Investor will purchase from the Company, at the Closing (as defined below), (i) six million (6,000,000) shares (the “Shares”) of Common Stock, and (ii) non-cashless warrants to purchase three million (3,000,000) additional shares of Common Stock on the terms set forth in the Common Stock Purchase Warrants attached hereto as Exhibit C, all in consideration for the right to receive ten million five hundred thirty six thousand three hundred fifteen (10,536,315) cryptographic tokens, known as “IRON,” of the Investor (the “Tokens”).
  
 1.2 Closing. The purchase and sale of the Shares shall take place remotely via the exchange of documents and signatures (the “Closing”) on the first business day following the satisfaction or waiver of the conditions set forth in Section 4 and Section 5 (other than those conditions that by their nature are to be satisfied at or immediately prior to the Closing, but subject to the satisfaction or waiver of those conditions) or at such other date, time and place as the Company and the Investor may agree in writing (the “Closing Date”). At the Closing, the Company will deliver or cause to be delivered to the Investor a copy of the irrevocable instructions to the Company’s transfer agent instructing such transfer agent to issue the Shares into book-entry form to the Investor and, concurrently, the Investor and the Company shall enter into the Simple Agreement for Future Token, attached hereto as Exhibit A (the “SAFT”), which shall grant the Company the right to receive the Tokens on the terms and subject to the conditions set forth in the SAFT.
  
 SECTION 2
  
 Representations and Warranties of the Company
  
 Except as set forth on the Schedule of Exceptions attached hereto as Exhibit B, the Company hereby represents and warrants the following as of the Execution Date:
  
 2.1 Organization and Good Standing and Qualifications. The Company is a corporation duly organized, validly existing and in good standing under the State of Nevada and has all requisite power and authority to own, lease, operate and occupy its properties and to carry on its business as now being conducted. Except as set forth on the Schedule of Exceptions, the Company does not own more than fifty percent (50%) of the outstanding capital stock of or control any other business entity. The Company is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which the nature of the business conducted or property owned or leased by it makes such qualification necessary, other than those in which the failure so to qualify or be in good standing would not have a Material Adverse Effect. For purposes of this Agreement, “Material Adverse Effect” shall mean any event or condition that would reasonably be likely to have a material adverse effect on the business, operations, properties, prospects or financial condition of the Company and its consolidated subsidiaries, taken as a whole, or adversely affect in any material respect the ability of the Company to perform its obligations, or Investor’s rights, under this Agreement.
   	 
	1
	 
 
	 

  
 2.2 Authorization. (i) The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement; (ii) the execution and delivery of this Agreement by the Company, the consummation by the Company of the transactions contemplated hereby and thereby and the issuance, sale and delivery of the Shares have been duly authorized by all necessary corporate action, and no further consent or authorization of the Company, its board of directors or its shareholders is required; and (iii) this Agreement has been duly executed and delivered and constitutes a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, securities, insolvency, or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies, or indemnification or by other equitable principles of general application.
  
 2.3 Valid Issuance of Shares. The issuance of the Shares has been duly authorized by all requisite corporate action. When the Shares are issued, sold and delivered in accordance with the terms of this Agreement for the consideration expressed herein, the Shares will be duly and validly issued and outstanding, fully paid, and nonassessable, and will be free of all liens and restrictions on transfer other than restrictions on transfer under applicable state and federal securities laws and the Investor shall be entitled to all rights accorded to a holder of shares of Common Stock. The Company has reserved a sufficient number of shares of Common Stock for issuance to the Investor in accordance with the Company’s obligations under this Agreement.
  
 2.4 No Conflict. The execution, delivery and performance by the Company of this Agreement and the consummation of the transactions contemplated hereby do not and will not (i) contravene or conflict with the Articles of Incorporation of the Company, (ii) contravene or conflict with or violate any federal, state, local or foreign statute, rule, regulation, judgment, order, writ or decree binding upon or applicable to the Company, (iii) contravene or conflict with or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any material contract or other material agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or obligation binding upon or applicable to the Company, or (iv) create or impose a lien, charge or encumbrance on any property of the Company under any agreement or other commitment to which the Company is a party or by which the Company is bound, in the case of each of clauses (iii) and (iv), which would have a Material Adverse Effect.
  
 2.5 Consents. Except for the consents that have been obtained on or prior to the Closing or filings required to be made by the Company with federal or state securities commissions or the OTC Markets Group Inc. (“OTC Market”), no consent, approval, license, order, authorization, registration, declaration or filing with or of any governmental entity or other person is required to be done or obtained by the Company in connection with (i) the execution and delivery by the Company of this Agreement, (ii) the performance by the Company of its obligations under this Agreement, (iii) the consummation by the Company of any of the transactions contemplated by this Agreement, including the issuance and sale of the Shares in accordance with the terms hereof.
  
 2.6 Compliance. The Company is not, and the execution and delivery of this Agreement and the consummation of the transactions contemplated herewith will not cause the Company to be (i) in violation or default of any provision of any instrument, mortgage, deed of trust, loan, contract, or commitment, (ii) in violation of any provision of any judgment, decree, order or obligation to which it is a party or by which it or any of its properties or assets are bound, or (iii) in violation of any federal, state or, to its knowledge, local statute, rule or governmental regulation, in the case of each of clauses (i), (ii) and (iii), which would have a Material Adverse Effect.
   	 
	2
	 
 
	 

  
 2.7 Capitalization. Immediately prior to the Execution Date, a total of 124,035,891 shares of Common Stock are issued and outstanding, 10,000,000 shares of Preferred Stock are authorized, of which 3,000,000 shares are designated Series A Preferred Stock, with 2,060,000 shares of Series A Preferred Stock issued and outstanding, and 165,000 shares of which are designated Series B Preferred Stock, all of which are issued and outstanding. The outstanding shares of capital stock of the Company have been duly and validly issued and are fully paid and nonassessable, were not issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities, and have been issued in compliance with all federal and state securities laws, in each case except as would not reasonably be expected to have a Material Adverse Effect. Except as set forth in the OTC Documents (as defined below), there are no outstanding rights (including, without limitation, preemptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any unissued shares of capital stock or other equity interest in the Company, or any contract, commitment, agreement, understanding or arrangement of any kind to which the Company is a party and relating to the issuance or sale of any capital stock of the Company, any such convertible or exchangeable securities or any such rights, warrants or options. Without limiting the foregoing, no preemptive right, co-sale right, right of first refusal, registration right, or other similar right exists with respect to the Shares or the issuance and sale thereof. There are no shareholder agreements, voting agreements or other similar agreements with respect to the voting of the Shares to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s shareholders.
  
 2.8 OTC Documents, Financial Statements. The Common Stock is currently listed or traded on the OTC Market, and the Company has timely filed all reports, schedules, forms, statements and other documents required to be filed by the Company with the OTC Market pursuant to the reporting requirements for listing as a OTC company (all of the foregoing, including filings incorporated by reference therein, being referred to herein as the “OTC Documents”). The Company is not in violation of the listing requirements of the OTC Market and has no knowledge of any facts that would reasonably lead to delisting or suspension of its Common Stock from the OTC Market in the foreseeable future. As of its date, each OTC Document filed complied in all material respects with the requirements of the OTC Market and the rules and regulations of the OTC Market promulgated thereunder applicable to such document, and, as of its date, after giving effect to the information disclosed and incorporated by reference therein, no such OTC Document contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. As of their respective dates, the financial statements of the Company included in the OTC Documents filed with the OTC Market, compiled as to form and substance in all material respects with applicable accounting requirements and the published rules and regulations of the OTC Market or other applicable rules and regulations with respect thereto. Such financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) applied on a consistent basis during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or summary statements), and fairly present in all material respects the financial position of the Company as of the dates thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments).
  
 2.9 Internal Controls and Procedures. The Company maintains adequate disclosure controls and procedures. Such disclosure controls and procedures are effective as of the latest date of management’s evaluation of such disclosure controls and procedures to ensure that all material information required to be disclosed by the Company in the reports that it files or furnishes to the OTC Market is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the OTC Market. The Company maintains a system of internal controls over financial reporting sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; and (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP.
  
 2.10 Material Adverse Change. Except as disclosed in the OTC Documents, since January 31, 2018, no event or series of events has or have occurred that would, individually or in the aggregate, have a Material Adverse Effect.
  
 2.11 No Undisclosed Liabilities. To the Company’s knowledge, the Company and its consolidated subsidiaries, taken as a whole, do not have any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company and its consolidated subsidiaries (including the notes thereto) in conformity with GAAP and are not disclosed in the OTC Documents, other than those incurred in the ordinary course of the Company’s or its subsidiaries’ respective businesses since January 31, 2018.
  
 2.12 No Undisclosed Events or Circumstances. Except for the transactions contemplated by this Agreement, event or circumstance has occurred or exists with respect to the Company, its subsidiaries, or their respective businesses, properties, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed and which, individually or in the aggregate, would have a Material Adverse Effect.
   	 
	3
	 
 
	 

  
 2.13 Actions Pending. There is no action, suit, claim, investigation or proceeding pending or, to the knowledge of the Company, threatened against the Company or any subsidiary which questions the validity of this Agreement or the transactions contemplated hereby or any action taken or to be taken pursuant hereto. Except as set forth in the OTC Documents, there is no material action, suit, claim, investigation or proceeding pending or, to the knowledge of the Company, threatened, against or involving the Company, any subsidiary, or any of their respective properties or assets. Except as set forth in the OTC Documents, no material judgment, order, writ, injunction or decree or award has been issued by or, to the knowledge of the Company, requested of any court, arbitrator or governmental agency.
  
 2.14 Compliance with Law. The businesses of the Company and its subsidiaries have been and are presently being conducted in material compliance with all applicable federal, state and local governmental laws, rules, regulations and ordinances. The Company and each of its subsidiaries have all material franchises, permits, licenses, consents and other governmental or regulatory authorizations and approvals necessary for the conduct of its business as now being conducted by it, except for such franchises, permits, licenses, consents and other governmental or regulatory authorizations and approvals, the failure to possess which, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect.
  
 2.15 Exemption from Registration, Valid Issuance. Subject to, and in reliance on, the representations, warranties and covenants made herein by the Investor, the issuance and sale of the Shares in accordance with the terms and on the bases of the representations and warranties set forth in this Agreement, may be issued and sold without registration under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) thereof. The sale and issuance of the Shares pursuant to, and the Company’s performance of its obligations under, this Agreement will not (i) result in the creation or imposition of any liens, charges, claims or other encumbrances upon the Shares or any of the assets of the Company, or (ii) entitle the holders of any outstanding shares of capital stock of the Company to preemptive or other rights to subscribe to or acquire the Shares or other securities of the Company.
  
 2.16 Transfer Taxes. All stock transfer or other taxes (other than income taxes) that are required to be paid in connection with the sale and transfer of the Shares to be sold to Investor hereunder will be, or will have been, fully paid or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with.
  
 2.17 Investment Company. The Company is not, and after giving effect to the offering and sale of the Shares will not be, an “investment company” as defined in the Investment Company Act of 1940, as amended.
  
 2.18 Brokers. No brokers, finders or financial advisory fees or commissions will be payable by the Company or any of its subsidiaries in respect of the transactions contemplated by this Agreement.
  
 SECTION 3
  
 Representations and Warranties of the Investor
  
 The Investor hereby represents and warrants the following as of the Execution Date:
  
 3.1 Experience. The Investor is experienced in evaluating companies such as the Company, has such knowledge and experience in financial and business matters that the Investor is capable of evaluating the merits and risks of the Investor’s perspective investment in the Company, and has the ability to bear the economic risks of the investment.
  
 3.2 Investment. The Investor is acquiring the Shares for investment for the Investor’s own account and not with the view to, or for resale in connection with, any distribution thereof. The Investor understands that the Shares have not been and will not be registered under the Securities Act by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent as expressed herein. The Investor further represents that it does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participation to any third person with respect to any of the Shares.
   	 
	4
	 
 
	 

  
 3.3 Rule 144. The Investor is aware of the provisions of Rule 144 promulgated under the Securities Act which permit limited resale of shares purchased in a private placement subject to the satisfaction of certain conditions. In connection therewith, the Investor acknowledges that the Company will make a notation on its stock books regarding the restrictions on transfers set forth in this Section 3, subject to Section 6.3, and will transfer the Shares on the books of the Company only to the extent not inconsistent herewith and therewith.
  
 3.4 Access to Information. The Investor has received and reviewed information about the Company and has had an opportunity to discuss the Company’s business, management and financial affairs with its management and to review the Company’s facilities. The Investor has had a full opportunity to ask questions of and receive answers from the Company, or any person or persons acting on behalf of the Company, concerning the terms and conditions of an investment in the Shares. The Investor is not relying upon, and has not relied upon, any statement, representation or warranty made by any person, except for the statements, representations and warranties contained in this Agreement.
  
 3.5 Authorization. This Agreement when executed and delivered by the Investor will constitute a valid and legally binding obligation of the Investor, enforceable in accordance with its terms, subject to: (i) judicial principles respecting election of remedies or limiting the availability of specific performance, injunctive relief, and other equitable remedies; and (ii) bankruptcy, insolvency, reorganization, moratorium or other similar laws now or hereafter in effect generally relating to or affecting creditors’ rights.
  
 3.6 Investor Status. The Investor acknowledges that it is an “accredited investor” as defined in Rule 501(a) of Regulation D of the Securities Act, and the Investor shall submit to the Company such further assurances of such status as may be reasonably requested by the Company.
  
 3.8 No Conflicts. The execution, delivery and performance by the Investor of this Agreement do not and will not (i) contravene or conflict with the organizational documents of the Investor, (ii) contravene or conflict with or constitute a default under any material provision of any law binding upon or applicable to the Investor or (iii) contravene or conflict with or constitute a default under any material contract or other material agreement, judgment, order, writ, injunction, citation, award or decree binding upon or applicable to the Investor.
  
 3.9 Consent. No consent, approval, license, order, authorization, registration, declaration or filing with or of any governmental entity or other person is required to be done or obtained by the Investor in connection with (i) the execution and delivery by the Investor of this Agreement, (ii) the performance by the Investor of its obligations under this Agreement or (iii) the consummation by the Investor of any of the transactions contemplated by this Agreement.
  
 SECTION 4
  
 Conditions to Investor’s Obligations at Closing
  
 The obligations of the Investor under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions, any of which may be waived in writing by the Investor (except to the extent not permitted by law):
  
 4.1 No Injunction, etc. No preliminary or permanent injunction or other binding order, decree or ruling issued by a court or governmental agency shall be in effect which shall have the effect of preventing the consummation of the transactions contemplated by this Agreement. No action or claim shall be pending before any court or quasi- judicial or administrative agency of any federal, state, local or foreign jurisdiction or before any arbitrator wherein an unfavorable injunction, judgment, order, decree, ruling or charge would be reasonably likely to (i) prevent consummation of any of the transactions contemplated by this Agreement, (ii) cause any of the transactions contemplated by this Agreement to be rescinded following consummation or (iii) have the effect of making illegal the purchase of, or payment for, any of the Shares by the Investor.
   	 
	5
	 
 
	 

  
 4.2 Representations and Warranties. The representations and warranties of the Company contained in Section 2 shall have been true and correct in all material respects (except for such representations and warranties that are qualified by “materiality” or “Material Adverse Effect” which shall be true and correct in all respects) on and as of the Closing with the same effect as though such representations and warranties had been made on and as of the Closing.
  
 4.3 Performance. The Company shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing.
  
 4.5 Securities Laws. The offer and sale of the Shares to the Investor pursuant to this Agreement shall be exempt from the registration requirements of the Securities Act and the registration and/or qualification requirements of all applicable state securities laws.
  
 4.6 Authorizations. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall have been duly obtained and shall be effective on and as of the Closing.
  
 SECTION 5
  
 Conditions to the Company’s Obligations at Closing
  
 The obligations of the Company to the Investor under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions by the Investor:
  
 5.1 Representations and Warranties. The representations and warranties of the Investor contained in Section 3 shall be true and correct in all material respects (except for such representations and warranties that are qualified by materiality which shall be true and correct in all respects) on and as of the Closing with the same effect as though such representations and warranties had been made on and as of the Closing.
  
 5.2 Securities Law Compliance. The offer and sale of the Shares to the Investor pursuant to this Agreement shall be exempt from the registration requirements of the Securities Act and the registration and/or qualification requirements of all applicable state securities laws.
  
 5.3 Authorization. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall have been duly obtained and shall be effective on and as of the Closing.
  
 SECTION 6
  
 Resales; Covenants
  
 6.1 Participation Right.
  
 (a) The Investor hereby grants the Company the right of first refusal to purchase up to the Company Investment Share (as defined below) of equity securities (the “Equity Securities”) issued in the Investor’s next round of Equity Financing (as defined below). However, the Company will have no right to purchase any Equity Securities if the Company cannot demonstrate to the Investor’s reasonable satisfaction that the Company is at the time of the proposed issuance of the Equity Securities an “accredited investor” as such term is defined in Regulation D under the Securities Act.
   	 
	6
	 
 
	 

  
 (b) If the Investor proposes to undertake an issuance of Equity Securities, it shall give notice to the Company of its intention to issue Equity Securities (the “Notice”), describing the type of Equity Securities and the price and the general terms upon which the Company proposes to issue the Equity Securities. The Company will have ten (10) days from the date of the Notice to agree in writing to purchase the Company’s share of such Equity Securities for the price and upon the general terms specified in the Notice by giving written notice to the Company and stating therein the quantity of Equity Securities to be purchased (not to exceed the Company Investment Share, unless agree to in writing by the Investor).
  
 (c) In connection with any issuance of Equity Securities by the Investor to the Company pursuant to this Section 6.1, the Company will execute and deliver to the Investor all transaction documents related to the Equity Financing; provided, that these documents are the same or similar to the documents to be entered into with other purchasers of Equity Securities.
  
 (c) “Equity Financing” means a bona fide transaction or series of transactions pursuant in which the Investor issues and sells capital stock with the principal purpose of raising capital (other than in connection with a sale of tokens or a right to receive tokens).
  
 (d) “Company Investment Share” means Equity Securities representing three percent (3.00%) of the Investor’s total outstanding shares of capital stock immediately following the Equity Financing.
  
 6.2 Rule 144 Reporting. With a view to making available to the Investor the benefits of certain rules and regulations of the Securities and Exchange Commission (the “Commission”) that may permit the sale of the Shares to the public without registration and, in each case, for so long as the Investor holds Shares that are not freely transferable without restriction under the Securities Act (including the current public information requirement under Rule 144), the Company agrees to use commercially reasonable efforts to:
  
 (a) Make and keep public information available, as those terms are understood and defined in Rule 144 promulgated under the Securities Act;
  
 (b) File with the OTC Market in a timely manner all reports and other documents required of the Company by the OTC Market; and
  
 (c) Furnish the Investor forthwith upon request (i) a written statement by the Company as to its compliance with the public information requirements of said Rule 144, (ii) a copy of the most recent annual or quarterly report of the Company, and (iii) such other reports and documents as may be reasonably requested in availing the Investor of any rule or regulation of the Commission permitting the sale of any such securities without registration.
  
 6.3 Restrictive Legend. The Investor agrees to the imprinting on any stock certificates, so long as is required by this Section 6, of a restrictive legend in substantially the following form:
  
 “THE SECURITIES EVIDENCED OR CONSTITUTED HEREBY HAVE BEEN ISSUED WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND MAY NOT BE SOLD, OFFERED FOR SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED WITHOUT REGISTRATION UNDER THE ACT UNLESS EITHER (i) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL, IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY, TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED IN CONNECTION WITH SUCH DISPOSITION OR (ii) THE SALE OF SUCH SECURITIES IS MADE PURSUANT TO SECURITIES AND EXCHANGE COMMISSION RULE 144.”
   	 
	7
	 
 
	 

  
 The legend set forth in this Section 6.3 and the related notation in the Company’s register of shareholders shall be removed and the Company shall issue a certificate without such legend or any other legend to the holder of the Shares, if (i) the Shares are registered for resale under the Securities Act, (ii) the Shares are sold or transferred in compliance with to Rule 144 and the Company has received such customary certifications and other information as it shall have reasonably requested to demonstrate compliance of such transfer or sale with Rule 144, or (iii) the Shares are eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public information required under Rule 144. Following Rule 144 becoming available for the resale of Shares, without the requirement for the Company to be in compliance with the current public information required under Rule 144, the Company shall (at the Company’s expense), upon the written request of Investor, cause its counsel to issue to the Company’s transfer agent a legal opinion authorizing the issuance of a certificate representing the Shares without any restrictive or other legends, if requested by such transfer agent.
  
 6.4 Listing. Promptly following the date hereof, the Company shall prepare and submit to the OTC Market a listing application covering the Shares, together with all other documents required by the OTC Market to be submitted in support thereof.
  
 6.5 Further Assurances. Each of the Investor and the Company shall execute such further documents and shall take, or shall cause to be taken, such further actions as may be reasonably required to carry out the provisions of this Agreement and give effect to the transactions contemplated hereby.
  
 SECTION 7
  
 Indemnification
  
 7.1 Each party (an “Indemnifying Party”) hereby indemnifies and holds harmless the other party, such other party’s respective officers, directors, employees, consultants, representatives and advisers, and any and all Affiliates of the foregoing (each of the foregoing, an “Indemnified Party”) from and against all losses, liabilities, costs, damages and expense (including reasonable legal fees and expenses) (collectively, “Losses”) suffered or incurred by any such Indemnified Party to the extent arising from, connected with or related to (a) breach of any representation or warranty of such Indemnifying Party in this Agreement; and (b) breach of any covenant or undertaking of any Indemnifying Party in this Agreement. If an event or omission (including, without limitation, any claim asserted or action or proceeding commenced by a third party) occurs which an Indemnified Party asserts to be an indemnifiable event pursuant to this Section 7, the Indemnified Party will provide written notice to the Indemnifying Party, setting forth the nature of the claim and the basis for indemnification under this Agreement. The Indemnified Party will give such written notice to the Indemnifying Party immediately after it becomes aware of the existence of any such event or occurrence. Such notice will be a condition precedent to any obligation of the Indemnifying Party to act under this Agreement but will not relieve it of its obligations under the indemnity except to the extent that the failure to provide prompt notice as provided in this Agreement prejudices the Indemnifying Party with respect to the transactions contemplated by this Agreement and to the defense of the liability. In case any such action is brought by a third party against any Indemnified Party and it notifies the Indemnifying Party of the commencement thereof, the Indemnifying Party will be entitled to participate therein and, to the extent that it wishes, to assume the defense and settlement thereof with counsel reasonably selected by it and, after notice from the Indemnifying Party to the Indemnified Party of such election so to assume the defense and settlement thereof, the Indemnifying Party will not be liable to the Indemnified Party for any legal expenses of other counsel or any other expenses subsequently incurred by such Indemnified Party in connection with the defense thereof, provided, however, that an Indemnified Party shall have the right to employ separate counsel at the expense of the Indemnifying Party if (i) the employment thereof has been specifically authorized in writing by the Indemnifying Party; or (ii) representation of both parties by the same counsel would be inappropriate due to actual or potential conflicts of interests between such parties (which such judgment shall be made by the Indemnified Party in good faith after consultation with counsel). The Indemnified Party agrees to cooperate fully with (and to provide all relevant documents and records and make all relevant personnel available to) the Indemnifying Party and its counsel, as reasonably requested, in the defense of any such asserted claim at no additional cost to the Indemnifying Party. No Indemnifying Party will consent to the entry of any judgment or enter into any settlement with respect to any such asserted claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld or delayed, (A) if such judgment or settlement does not include as an unconditional term thereof the giving by each claimant or plaintiff to each Indemnified Party of a release from all liability in respect to such claim or (B) if, as a result of such consent or settlement, injunctive or other equitable relief would be imposed against the Indemnified Party or such judgment or settlement could materially and adversely affect the business, operations or assets of the Indemnified Party. No Indemnified Party will consent to the entry of any judgment or enter into any settlement with respect to any such asserted claim without the prior written consent of the Indemnifying Party, not to be unreasonably withheld or delayed. If an Indemnifying Party makes a payment with respect to any claim under the representations or warranties set forth herein and the Indemnified Party subsequently receives from a third party or under the terms of any insurance policy a sum in respect of the same claim, the receiving party will repay to the other party such amount that is equal to the sum subsequently received.
   	 
	8
	 
 
	 

  
 7.2 Limitations on Liability. No party hereto shall be liable for any punitive or special damages under this Section 7 (and no claim for indemnification hereunder shall be asserted) as a result of any breach or violation of any covenant or agreement of such party (including under this Section 7) in or pursuant to this Agreement.
  
 7.3 Exclusive Remedy. The rights of the parties hereto pursuant to (and subject to the conditions of) this Section 7 shall be the sole and exclusive remedy of the parties hereto and their respective Affiliates with respect to any Losses (whether based in contract, tort or otherwise) resulting from or relating to any breach of the representations, warranties covenants and agreements made under this Agreement or any certificate, document or instrument delivered hereunder, and each party hereto hereby waives, to the fullest extent permitted under applicable law, and agrees not to assert after Closing, any other claim or action in respect of any such breach. Notwithstanding the foregoing, claims for common law fraud shall not be waived or limited in any way by this Section 7.
  
 7.4 Affiliates. For all purposes of this Agreement, the term “Affiliate” means, with respect to a specified entity, an entity that directly or indirectly through one or more intermediaries, is controlled by the entity, in each case where the term “control” means possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of an entity, whether through ownership of voting securities, by contract interest or otherwise.
  
 SECTION 8
  
 Miscellaneous
  
 8.1 Governing Law. This Agreement shall be governed in all respects by the laws of California as applied to agreements entered into and performed entirely in the State of California by residents thereof.
  
 8.2 Survival. The representations, warranties, covenants and agreements made herein shall survive any investigation made by the Investor and the Closing until the expiration of the applicable statute of limitations.
  
 8.3 Successors, Assigns. Except as otherwise provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. This Agreement may not be assigned by either party without the prior written consent of the other; except that either party may assign this Agreement to an Affiliate of such party or to any third party that acquires all or substantially all of such party’s business, whether by merger, sale of assets or otherwise.
  
 8.4 Notices. All notices and other communications required or permitted hereunder shall be in writing and shall be sent by electronic mail or mailed by registered or certified mail, postage prepaid, return receipt requested, or otherwise delivered by hand or by messenger, addressed
  
 if to the Investor, at the following address: 
  
 Robot Cache, S.L.
 Calle El Pilar No. 5
 Edificio Peceno Local 9
 38002 Santa Cruz se Tenerife, Spain 
 Attention: Lee Jacobson, CEO
 E-mail: lee@robotcache.com
   	 
	9
	 
 
	 

  
 if to the Company, at the following address: 
  
 Millennium Blockchain Inc.
 11700 W. Charleston Blvd., Suite 73 
 Las Vegas, Nevada 89135 
 Attention: Brandon Romanek, CEO 
 E-mail: brandon@mblockchain.io
  
 or at such other address as one party shall have furnished to the other party in writing. All notices and communications under this Agreement shall be deemed to have been duly given (i) when delivered by hand, if personally delivered, (ii) when received by a recipient, if sent by email, or (iii) one business day following sending within the United States by overnight delivery via commercial one-day overnight courier service.
  
 8.5 Expenses. Each of the Company and the Investor shall bear its own expenses and legal fees incurred on its behalf with respect to this Agreement and the transactions contemplated hereby.
  
 8.6 Finder’s Fees. Each of the Company and the Investor shall indemnify and hold the other harmless from any liability for any commission or compensation in the nature of a finder’s fee, placement fee or underwriter’s discount (including the costs, expenses and legal fees of defending against such liability) for which the Company or the Investor, or any of its respective partners, employees, or representatives, as the case may be, is responsible.
  
 8.7 Counterparts. This Agreement may be executed in counterparts, each of which shall be enforceable against the party actually executing the counterpart, and all of which together shall constitute one instrument. Delivery of an executed counterpart of a signature page of this Agreement in Portable Document Format (PDF) or by facsimile transmission shall be effective as delivery of a manually executed original counterpart of this Agreement.
  
 8.8 Severability. In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision; provided that no such severability shall be effective if it materially changes the economic benefit of this Agreement to any party.
  
 8.9 Entire Agreement. This Agreement, including the exhibits and schedules attached hereto and thereto, constitute the full and entire understanding and agreement among the parties with regard to the subjects hereof and thereof. No party shall be liable or bound to any other party in any manner with regard to the subjects hereof or thereof by any warranties, representations or covenants except as specifically set forth herein or therein.
  
 8.10 Waiver. The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party. None of the terms, covenants and conditions of this Agreement can be waived except by the written consent of the party waiving compliance.
  
 [Signature Page Follows]
   	 
	10
	 
 
	 

  
 IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first set forth above.
  
 	  
	 COMPANY
  
 MILLENNIUM BLOCKCHAIN INC.
	  

	  
	  
	  
	  

	  
	 By:
	 
	  

	  
	 Name:
	 Brandon Romanek
	  

	  
	 Title:
	 Chief Executive Officer
	  

	  
	  
	  
	  

	  
	 INVESTOR
  
 ROBOT CACHE, S.L.
	  

	  
	  
	  
	  

	  
	 By:
	 
	  

	  
	 Name:
	 Lee Jacobson
	  

	  
	 Title:
	 Chief Executive Officer
	  

   	 
	11
	 
 
	 

  
 EXHIBIT A
  
 SAFT
   
  
  
  
  
  	 
	12
	 
 
	 

  
 EXHIBIT B
  
 SCHEDULE OF EXCEPTIONS
   
  
  
  
  
  	 
	13
	 
 
	 

  
 EXHIBIT C
  
 COMMON STOCK PURCHASE WARRANTS
  
   
  
  
  	 
	14EXHIBIT 10.1

 

EXECUTION VERSION

 

 

lHARVARD BIOSCIENCE, INC. 

EMPLOYMENT AGREEMENT

 

This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is
made as of the 18th day of October, 2018, between Harvard Bioscience, Inc., a Delaware corporation (the “Company”),
and Kam Unninayar (“Executive”).  For purposes of this Agreement the “Company” shall refer to the
Company and any of its predecessors.

 

WHEREAS, the Company desires to employ Executive and Executive
desires to be employed by the Company on the terms contained herein.

 

NOW, THEREFORE, in consideration of the mutual covenants
and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the parties agree as follows:

 

1. Employment. The term of this Agreement shall extend
from November 26, 2018 (the “Commencement Date”) until November 26, 2019; provided, however, that the term of this
Agreement shall automatically be extended for two additional years following the end of the term then in effect unless, not less
than 90 days prior to each such date, either party shall have given written notice to the other that it does not wish to extend
this Agreement; provided, further, that if a Change in Control occurs during the original or extended term of this Agreement, the
term of this Agreement shall, notwithstanding anything in this sentence to the contrary, continue in effect for a period of not
less than twelve (12) months beyond the month in which the Change in Control occurred. The term of this Agreement shall
be subject to termination as provided in Paragraph 7 and may be referred to herein as the “Period of Employment.”

 

2. Position and Duties. During the Period of
Employment, Executive shall serve as the Chief Financial Officer of the Company, and shall have such powers and duties as may from
time to time be prescribed by the Board of Directors (the “Board”) or the Chief Executive Officer of the Company, provided
that such duties are consistent with Executive’s position or other positions that she may hold from time to time. Executive
shall devote her full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, Executive
may serve on no more than two other boards of directors with the approval of the Board as long as such service does not materially
interfere with Executive’s performance of her duties to the Company as provided in this Agreement or otherwise breach any
obligations of Executive to the Company.

 

3. Compensation and Related Matters. 

 

(a)       Base Salary. Executive’s
initial base salary shall be $28,333.33 per month (which annualizes to Three Hundred Forty Thousand dollars ($340,000)). Executive’s
base salary shall be redetermined each fiscal year during the term of this Agreement by the Board or a Committee thereof, beginning
with fiscal year 2019. The base salary in effect at any given time is referred to herein as “Base Salary.” The Base
Salary shall be payable in substantially equal installments on a bi-weekly or more frequent basis.

 

(b)       Incentive Compensation.
In addition to Base Salary, commencing with fiscal year 2019 and each fiscal year thereafter while this Agreement is in
effect, Executive shall be eligible to receive cash incentive compensation of up to a fifty percent (50%) of Executive’s
Base Salary upon meeting objectives as determined by the Board or a Committee thereof from time to time in their sole discretion,
and such bonus being subject to a 0 to 2x multiplier depending on individual and Company performance as determined by the Board
or a Committee thereof from time to time in their sole discretion. This annual bonus is referred to in this Agreement as the “Annual
Bonus.” Any such Annual Bonus that is earned shall be paid in accordance the Company’s policies and procedures regarding
the payment of cash incentive compensation, subject to Paragraph 8 below. The Executive shall also be eligible to participate in
such other incentive compensation plans as the Board or a Committee thereof shall determine from time to time for its senior executive
officers.

 

(c)       Expenses. Executive shall be entitled
to receive prompt reimbursement for all reasonable expenses incurred by her in performing services hereunder during the Period
of Employment, in accordance with the Company policies and procedures then in effect for its senior executive officers, provided
that such reimbursement does not occur later than the end of the second calendar year after the calendar year in which such expense
was incurred.

 

    

    

    

 

(d)       Other Benefits. During the Period
of Employment, Executive shall be entitled to continue to participate in or receive benefits under all of the Company’s Employee
Benefit Plans, or under plans or arrangements that provide no less favorable treatment to the Executive than the Employee Benefit
Plans provided to other, similarly situated, members of the Company’s senior management. As used herein, the term “Employee
Benefit Plans” includes, without limitation, each pension and retirement plan; supplemental pension, retirement and deferred
compensation plan; savings and profit-sharing plan; stock ownership plan; stock purchase plan; stock option plan; life insurance
plan; medical insurance plan; disability plan; and health and accident plan or arrangement established and maintained by the Company
on the date hereof or anytime hereafter. The Executive's participation in the Employee Benefit Plans will be subject to the terms
and conditions of each such Employee Benefit Plans, including eligibility and compliance requirements, as well as any limitations
imposed by applicable laws. To the extent that the scope or nature of benefits described in this section is determined under the
Company policies based on the seniority or tenure of an employee’s service, Executive shall be deemed to have tenure with
the Company equal to the actual time of Executive’s service with the Company. During the Period of Employment, Executive
shall be entitled to participate in or receive benefits under any Employee Benefit Plans which may, in the future, be made available
by the Company to its executives and key management employees, subject to and on a basis consistent with the terms, conditions
and overall administration of such Employee Benefit Plans. Any payments or benefits payable to Executive under an Employee
Benefit Plan referred to in this Subparagraph 3(d) in respect of any calendar year during which Executive is employed by the Company
for less than the whole of such year shall, unless otherwise provided in the applicable Employee Benefit Plan, be prorated in accordance
with the number of days in such calendar year during which she is so employed. Should any such payments or benefits accrue
on a fiscal (rather than calendar) year, then the proration shall be on the basis of a fiscal year rather than calendar year.

 

(e)       Vacations. Executive shall be entitled
to twenty (20) paid vacation days in each calendar year, which shall be accrued ratably during the calendar year. Executive
shall also be entitled to all paid holidays given by the Company to its executives.  Notwithstanding anything herein to the
contrary, Executive shall be paid any accrued and unused vacation upon separation of her service of employment with the Company,
if and as protected by applicable law.

 

(f)       Directors and
Officers Insurance and Indemnification. The Company shall also carry reasonable and customary D&O liability insurance
coverage for the benefit of its officers and directors, including Executive, during the term of this Agreement and for a customary
tail period following the termination of Executive’s employment or service as a member of the Board. Executive shall be entitled
to be indemnified by the Company to the fullest extent permitted by the applicable state law and consistent with Company’s
Second Amended and Restated Certificate of Incorporation, as amended.

 

4. Unauthorized Disclosure.

 

(a) Confidential Information. Executive acknowledges
that in the course of her employment with the Company (and, if applicable, its predecessors), she has been allowed to become, and
will continue to be allowed to become, acquainted with business affairs, information, trade secrets, and other matters which are
of a proprietary or confidential nature, including but not limited to the Company’s and its affiliates’ and predecessors’
operations, business opportunities, price and cost information, finance, customer information, business plans, various sales techniques,
manuals, letters, notebooks, procedures, reports, products, processes, services, and other confidential information and knowledge
concerning the Company and its affiliates’ and predecessors’ business (collectively the “Confidential Information”). The
Company agrees to provide on an ongoing basis such Confidential Information as the Company deems necessary or desirable to aid
Executive in the performance of her duties. Executive understands and acknowledges that such Confidential Information is confidential,
and she agrees not to disclose such Confidential Information to anyone outside the Company except to the extent that (i) Executive
deems such disclosure or use reasonably necessary or appropriate in connection with performing her duties on behalf of the Company;
(ii) Executive is required by order of a court of competent jurisdiction (by subpoena or similar process) to disclose or discuss
any Confidential Information, provided that in such case, Executive shall inform the Company of such event within 24 hours of receiving
notice of the court order, shall cooperate with the Company in attempting to obtain a protective order or to otherwise restrict
such disclosure, and shall only disclose Confidential Information to the minimum extent necessary to comply with any such court
order; (iii) such Confidential Information becomes generally known to and available for use in any industry in which the Company
does business (the “Industry”), other than as a result of any action or inaction by Executive; or (iv) such information
has been rightfully received by a member of the Industry or has been published in a form generally available to the Industry prior
to the date Executive proposes to disclose or use such information. Executive further agrees that she will not during her
employment with the Company and/or at any time thereafter use such Confidential Information in competing, directly or indirectly,
with the Company. At such time as Executive shall cease to be employed by the Company, she will immediately turn over to the
Company all Confidential Information, including papers, documents, writings, electronically stored information, other property,
and all copies of them provided to or created by him during the course of her employment with the Company.

 

    	2

    

    

 

(b) Heirs, successors, and legal representatives.
The foregoing provisions of this Paragraph 4 shall be binding upon Executive’s heirs, successors, and legal representatives. The
provisions of this Paragraph 4 shall survive the termination of this Agreement for any reason.

 

(c) Defend Trade Secrets Act Whistleblower Immunity.
 Executive acknowledges and understand that Executive shall not be held criminally or civilly liable under any Federal or State
trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government
official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected
violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made
under seal. Also, if Executive files a lawsuit for retaliation by an employer for reporting a suspected violation of law, Executive
may disclose the trade secret to Executive’s attorney and use the trade secret information in the court proceeding, provided
that Executive files any document containing the trade secret under seal and do not disclose the trade secret, except pursuant
to court order.

 

5. Covenant Not to Compete or Solicit or Hire.
In consideration for Executive’s employment by the Company under the terms provided in this Agreement, and more particularly
the terms set forth in Paragraph 10 as consideration for Paragraph 5(a), and as a means to aid in the performance and enforcement
of the terms of the provisions of Paragraph 4, Executive agrees that:

 

(a) during the term of Executive’s employment
with the Company and for a period of twelve (12) months thereafter, Executive will not, directly or indirectly, as an owner,
director, principal, agent, officer, employee, partner, consultant, servant, or otherwise, carry on, operate, manage, control,
or become involved in any manner with any business, operation, corporation, partnership, association, agency, or other person or
entity which is engaged in a business that produces or develops products that compete or may compete directly with any products
(i) which are produced or being developed by the Company or any affiliate of the Company or (ii) which the Company or any affiliate
of the Company has active plans to produce or develop as of the date of Executive’s termination of employment with the Company,
in any area or territory in which the Company or any affiliate of the Company conducts or has active plans to conduct operations
as of the date of the Executive’s termination of employment with the Company; provided, however, that the foregoing shall
not prohibit Executive from owning up to one percent (1%) of the outstanding stock of a publicly held company engaged in the
Industry. This Paragraph 5(a) shall not apply in the event that the Executive is terminated without Cause; and

 

(b) during the term of Executive’s employment
with the Company and for a period of twelve (12) months thereafter, regardless of the reason for termination of employment,
Executive will not directly or indirectly solicit or induce any present or future employee of the Company or any affiliate of the
Company to accept employment with Executive or with any business, operation, corporation, partnership, association, agency, or
other person or entity with which Executive may be associated, and Executive will not hire or employ or cause any business, operation,
corporation, partnership, association, agency, or other person or entity with which Executive may be associated to hire or employ
any present or future employee of the Company.

 

Should Executive violate any of the provisions of this Paragraph,
then in addition to all other rights and remedies available to the Company at law or in equity, the duration of this covenant shall
automatically be extended for the period of time from which Executive began such violation until she permanently ceases such violation.
Executive acknowledges and agrees that the terms and conditions of this Paragraph 5 are reasonable with respect to its duration,
geographic area and scope.

 

6.       Remedies.
Executive acknowledges that full compliance with the terms of this Agreement is necessary to protect the significant value of the
Confidential Information and the customer and business goodwill of the Company. Executive acknowledges that if she breaches this
Agreement, the Company will be irreparably harmed and money damages will not be an adequate remedy. As a result, Executive agrees
that, in the event Executive breaches or threatens to breach any of the terms or provisions of this Agreement, the Company shall
be entitled to a preliminary or permanent injunction, without posting a bond or other security, in order to prevent the continuation
of such harm. Executive acknowledges that nothing in this Agreement will prohibit the Company from also pursuing any other remedy
and all remedies are cumulative. The parties intend that the Company shall be entitled to a full one-year period of post-employment
conduct by the Executive that complies with this Agreement. Executive therefore agrees that the one-year restrictive period under
Sections 5(a) and (b) shall be respectively tolled for the same period that Executive engages in the prohibited conduct prior to
the Company’s discovery of such violation. If Executive breaches his or her fiduciary duty to the Company or unlawfully takes,
physically, or electronically, property belonging to the Company, the one year restrictive period set forth in Sections 5(a) and
(b) shall be extended to twenty-four (24) months.

 

    	3

    

    

 

7. Termination. Executive’s employment
hereunder may be terminated without any breach of this Agreement under the following circumstances:

 

(a) Death. Executive’s employment
hereunder shall terminate upon her death.

 

(b) Disability. If, as a result of Executive’s
incapacity due to physical or mental illness, Executive shall have been absent from her duties hereunder on a full-time basis for
one hundred eighty (180) calendar days in the aggregate in any twelve (12) month period, the Company may terminate Executive’s
employment hereunder.

 

(c) Termination by Company For Cause. At any
time during the Period of Employment, the Company may terminate Executive’s employment hereunder for Cause if such termination
is approved by not less than a majority of the Board at a meeting of the Board called and held for such purpose. For purposes
of this Agreement, “Cause” shall mean: (A) conduct by Executive constituting an act of willful misconduct
in connection with the performance of her duties, including, without limitation, misappropriation of funds or property of the Company
or any of its affiliates; (B) criminal or civil conviction of Executive, a plea of nolo contendere by Executive or conduct
by Executive that would reasonably be expected to result in injury to the reputation of the Company if she were retained in her
position with the Company, including, without limitation, conviction of a felony involving moral turpitude; (C) continued,
willful and deliberate non-performance by Executive of her duties hereunder (other than by reason of Executive’s physical
or mental illness, incapacity or disability); (D) a breach by Executive of any of the provisions contained in Paragraphs 4
and 5 of this Agreement; or (E) a violation by Executive of the Company’s material employment policies which has continued
following written notice of such violation from the Board. If the Company determines that any alleged Cause under subparts 7(c)(A),
(D), and (E) is reasonably susceptible to being cured, the Company shall provide Executive with written notice specifying the basis
for the alleged Cause and Executive shall have thirty (30) days to cure such Cause.

 

(d) Termination Without Cause. At any time during
the Period of Employment, the Company may terminate Executive’s employment hereunder without Cause if such termination is
approved by a majority of the Board at a meeting of the Board called and held for such purpose. Any termination by the Company
of Executive’s employment under this Agreement which does not constitute a termination for Cause under Subparagraph 7(c)
or result from the death or disability of the Executive under Subparagraphs 7(a) or (b) shall be deemed a termination without
Cause. If the Company provides notice to Executive under Paragraph 1 that it does not wish to extend the Period of Employment,
including a non-renewal at the end of the initial term or any renewal period, such action shall be deemed a termination without
Cause.

 

(e) Termination by Executive. At any time during
the Period of Employment, Executive may terminate her employment hereunder for any reason, including but not limited to Good Reason. If
Executive provides notice to the Company under Paragraph 1 that she does not wish to extend the Period of Employment, such
action shall be deemed a voluntary termination by Executive and one without Good Reason. For purposes of this Agreement, “Good
Reason” shall mean that Executive has complied with the “Good Reason Process” (hereinafter defined) following
the occurrence of any of the following events: (A) a substantial diminution or other substantial adverse change, not
consented to by Executive (or caused by her disability as elsewhere provided herein), in the nature or scope of Executive’s
responsibilities, authorities, powers, functions, duties or reporting relationship; (B) any removal, during the Period of
Employment, from Executive of her title of Chief Financial Officer; (C) an involuntary reduction in Executive’s Base
Salary except for across-the-board reductions similarly affecting all or substantially all executive officers; (D) a breach
by the Company of any of its other material obligations under this Agreement and the failure of the Company to cure such breach
within thirty (30) days after written notice thereof by Executive; (E) the involuntary relocation of the Company’s
offices at which Executive is principally employed on the Commencement Date or the involuntary relocation of the offices of Executive’s
primary workgroup to a location more than 30 miles from such offices, or the requirement by the Company that Executive be based
anywhere other than the Executives principal work location on the Commencement Date on an extended basis, except for required travel
on the Company’s business; or (F) the failure of the Company to obtain the agreement from any successor to the Company
to assume and agree to perform this Agreement as required by Paragraph 12 (each of which is hereinafter referred to as a “Good
Reason event”). “Good Reason Process” shall mean that (i) Executive reasonably determines in good faith
that a “Good Reason” event has occurred; (ii) Executive notifies the Company in writing of the occurrence of the
Good Reason event by no later than sixty (60) days after the initial occurrence of the event or condition constituting Good Reason;
(iii) Executive cooperates in good faith with the Company’s efforts, for a period not less than ninety (90) days
following such notice, to modify Executive’s employment situation; and (iv) notwithstanding such efforts, one or more
of the Good Reason events continues to exist and has not been modified in a manner acceptable to Executive. If the Company
cures the Good Reason event during the ninety (90) day period, Good Reason shall be deemed not to have occurred.

 

    	4

    

    

 

(f) Notice of Termination. Except for termination
as specified in Subparagraph 7(a), any termination of Executive’s employment by the Company or any such termination by Executive
shall be communicated by written Notice of Termination to the other party hereto and shall be effective on the Date of Termination
(as defined below). For purposes of this Agreement, a “Notice of Termination” shall mean a notice which shall
indicate the specific termination provision in this Agreement relied upon.

 

(g) Date of Termination. “Date of Termination”
shall mean: (A) if Executive’s employment is terminated by her death, the date of her death; (B) if Executive’s
employment is terminated on account of disability under Subparagraph 7(b) or by the Company for Cause under Subparagraph 7(c),
the date on which Notice of Termination is given or such later date as the Company may specify in the Notice of Termination; (C) if
Executive’s employment is terminated by the Company under Subparagraph 7(d), sixty (60) days after the date on which
a Notice of Termination is given or such later date as the Company may specify in the Notice of Termination (or, if such termination
occurs as a result of the Company providing notice to Executive under Paragraph 1 that it does not wish to extend the Period
of Employment, the date of the expiration of the current term of this Agreement); and (D) if Executive’s employment
is terminated by Executive under Subparagraph 7(e), thirty (30) days after the date on which a Notice of Termination is given
or, if such termination is without Good Reason, such later date up to sixty (60) days after the date on which such Notice
of Termination is given as Executive may specify in the Notice of Termination (or, if such termination occurs as a result of the
Company providing notice to Executive under Paragraph 1 that it does not wish to extend the Period of Employment, the date
of the expiration of the current term of this Agreement).

 

(h) Separation from Service. Notwithstanding anything
herein to the contrary, to the extent necessary to comply with Section 409A of the Internal Revenue Code of 1986, as amended (“Code”),
no event shall constitute a “termination of employment” in this Agreement, unless such event is also a “separation
from service,” as that term is defined for purposes of Section 409A and Treasury Regulation §1.409A-3(a)(1).

 

(i) Resignation of All Other Positions. Upon termination
of the Executive's employment hereunder for any reason, the Executive shall be deemed to have resigned from all positions that
the Executive holds as an officer or member of the board of directors (or a committee thereof) of the Company or any of its affiliates.

 

8. Compensation Upon Termination or During Disability.

 

(a) Death. If Executive’s employment terminates
by reason of her death, the Company shall, within sixty (60) days of death, pay in a lump sum to such person as Executive
shall designate in a notice filed with the Company or, if no such person is designated, to Executive’s estate, Executive’s
accrued and unpaid Base Salary to the date of her death, accrued and unused vacation, and if to the extent required by law, any
bonuses or other compensation actually earned for periods ended prior to the date of Executive’s death (including any Annual
Bonus for fiscal years ended prior to the date of death, if earned and not already paid) (collectively, the “Accrued Obligations”).
Upon the death of Executive, all unvested stock options and other stock-based equity awards shall immediately vest in full and,
if applicable, become exercisable, and Executive’s estate or other legal representatives may exercise the awards in accordance
with their terms.  Within ninety (90) days following the Date of Termination (but in no event later than March 15 of
the calendar year immediately after the calendar year in which the Date of Termination occurs), the Company shall pay as provided
above a cash lump sum equal to the value of COBRA premiums for a period of one (1) year following the Date of Termination
that may be used by the Executive’s spouse and dependents to pay for health insurance that is substantially similar to coverage
they received prior to the Date of Termination.  In addition to the foregoing, any payments to which Executive’s spouse,
beneficiaries, or estate may be entitled under any employee benefit plan shall also be paid in accordance with the terms of such
plan or arrangement. The payments made under this section shall fully discharge the Company’s obligations hereunder.

 

    	5

    

    

 

(b) Disability. During any period that Executive
fails to perform her duties hereunder as a result of incapacity due to physical or mental illness, Executive shall continue to
receive her Base Salary, until Executive’s employment is terminated due to disability in accordance with Subparagraph 7(b)
or until Executive terminates her employment in accordance with Subparagraph 7(e), whichever first occurs. Upon the Date of
Termination by reason of Executive’s disability, all unvested stock options and other stock-based equity awards shall immediately
vest and become exercisable.  If there is a dispute about whether Executive is disabled, the parties shall use the procedure
described in Paragraph 16, below, to resolve such dispute. If Executive’s employment is terminated due to disability in accordance
with Subparagraph 7(b), then the Company shall pay Executive all Accrued Obligations through the Date of Termination in a lump-sum
payment by no later than sixty (60) days after the Date of Termination. Within ninety (90) days following the Date of Termination
(but in no event later than March 15 of the calendar year immediately after the calendar year in which the Date of Termination
occurs), the Company shall pay to Executive a cash lump sum equal to the value of COBRA premiums for a period of one (1) year
following the Date of Termination that may be used by Executive to pay for health insurance coverage that is substantially similar
to the coverage Executive and her eligible dependents received prior to the Date of Termination.  Upon termination due to
death prior to the termination first to occur as specified in the preceding sentence, Subparagraph 8(a) shall apply.

 

(c) Resignation other than for Good Reason.
If Executive voluntarily resigns from employment other than for Good Reason as provided in Subparagraph 7(e), then the Company
shall pay Executive all Accrued Obligations through the Date of Termination in a lump-sum payment by no later than sixty (60) days
after the Date of Termination. Thereafter, the Company shall have no further obligations to Executive except as otherwise expressly
provided under this Agreement, provided any such termination shall not adversely affect or alter Executive’s rights under
any employee benefit plan of the Company in which Executive, at the Date of Termination, has a vested interest, unless otherwise
provided in such employee benefit plan or any agreement or other instrument attendant thereto.

 

(d) Termination by Executive for Good Reason or by the
Company without Cause. Subject to the terms of Paragraph 19(a), and subject to the terms of this section, if the Executive’s
employment is terminated for Good Reason as provided in Subparagraph 7(e) or without Cause as provided in Subparagraph 7(d), then
the Company shall pay Executive all Accrued Obligations through the Date of Termination in a lump-sum payment by no later than
sixty (60) days after the Date of Termination. In addition, subject to the Executive’s execution of a general release
of claims in the form attached hereto as Exhibit A within 21 days after the Date of Termination and the expiration of the
seven-day revocation period applicable thereto without the Executive revoking her acceptance of such general release, commencing
on the last day of the period for signing and revoking the general release of claims generally in the form set forth in Exhibit
A hereof (“Release”):

 

(i) the Company shall pay Executive an amount equal
to twelve (12) months of the Executive’s Base Salary rate at the Date of Termination (the “Severance Amount”).
The Severance Amount shall be paid in cash in equal installments over the period of one year from the date of commencement in accordance
with the Company’s standard payroll procedures.  Notwithstanding the foregoing, if the Executive breaches any of the
provisions contained in Paragraphs 4 and 5 of this Agreement, all payments of the Severance Amount shall immediately cease and
the entire Severance Amount shall be forfeited and become repayable to the Company to the extent paid. Furthermore, in the event
Executive terminates her employment for Good Reason as provided in Subparagraph 7(e), she shall be entitled to the Severance Amount
only if she provides the Notice of Termination provided for in Subparagraph 7(f) within thirty (30) days after she has complied
with the Good Reason Process;

 

(ii) on or before March 15 of the calendar year immediately
after the calendar year in which the Date of Termination occurs, the Company shall (i) reasonably determine what Annual Bonus the
Executive would have received had she remained employed throughout the fiscal year in which the Date of Termination occurs, and
(ii) if any such Annual Bonus would have been earned, then pay the Executive a pro rata portion of such determined Annual Bonus
by a lump-sum cash payment (where the pro rata amount is based on the number of days that Executive was employed during the applicable
fiscal year);

 

    	6

    

    

 

(iii) upon the Date of Termination, each unvested
stock-based grant and award held by Executive at the Date of Termination (including all stock options) that would vest within the
twelve (12) months following the Date of Termination shall accelerate and become fully vested or non-forfeitable; and

 

(iv) in addition to any other benefits to which
Executive may be entitled in accordance with the Company’s then existing severance policies, within ninety (90) days
following the Date of Termination (but in no event later than March 15 of the calendar year immediately after the calendar year
in which the Date of Termination occurs), the Company shall pay a cash lump sum equal to the value of COBRA premiums for a period
of one (1) year following the Date of Termination that may be used by Executive to pay for health insurance coverage that
is substantially similar to the coverage Executive and her eligible dependents received prior to the Date of Termination.

 

(e) Termination for Cause. If Executive’s
employment is terminated by the Company for Cause as provided in Subparagraph 7(c), then the Company shall pay Executive all Accrued
Obligations through the Date of Termination in a lump-sum payment by no later than sixty (60) days after the Date of Termination. Thereafter,
the Company shall have no further obligations to Executive except as otherwise expressly provided under this Agreement, provided
any such termination shall not adversely affect or alter Executive’s rights under any employee benefit plan of the Company
in which Executive, at the Date of Termination, has a vested interest, unless otherwise provided in such employee benefit plan
or any agreement or other instrument attendant thereto. In addition, except for the vested portion of the equity awards granted
in accordance with Paragraph 10 hereof, all stock options held by Executive as of the Date of Termination shall immediately terminate
and be of no further force and effect, and all other stock-based grants and awards shall be canceled or terminated in accordance
with their terms.

 

Nothing contained in the foregoing Subparagraphs 8(a) through 8(e) shall be construed
so as to affect Executive’s rights or the Company’s obligations relating to agreements or benefits which are unrelated
to termination of employment.

 

9. Change in Control Payment. The provisions
of this Paragraph 9 set forth certain terms of an agreement reached between Executive and the Company regarding Executive’s
rights and obligations upon the occurrence of a Change in Control of the Company. These provisions are intended to assure
and encourage in advance Executive’s continued attention and dedication to her assigned duties and her objectivity during
the pendency and after the occurrence of any such event.

 

(a) Change in Control. If within three (3)
months prior to, or twelve (12) months after the occurrence of the first event constituting a Change in Control, Executive’s
employment is terminated by the Company without Cause as provided in Subparagraph 7(d) or Executive terminates her employment for
Good Reason as provided in Subparagraph 7(e), then, subject to the terms of Paragraph 19(a), and subject to the Executive’s
executing a general release of claims in the form attached hereto as Exhibit A within 21 days after the Date of Termination
and the expiration of the seven-day revocation period applicable thereto without the Executive revoking her acceptance of such
general release, commencing on the last day of the period for signing and revoking the general release of claims in the form set
forth in Exhibit A hereof (“Release”):

 

(i) In lieu of any amounts otherwise payable pursuant
to Subparagraph 8(d)(i), the Company shall pay Executive a single lump sum in cash equal to eighteen (18) months of the Executive’s
Base Salary rate at the first event constituting a Change in Control;

 

(ii) Notwithstanding anything to the contrary in
any applicable option agreement or stock-based award agreement and in lieu of any acceleration of vesting that would otherwise
occur pursuant to Subparagraph 8(d)(iii), upon a Change in Control, all stock options and other stock-based awards granted to Executive
by the Company shall immediately accelerate and become exercisable or non-forfeitable as of the effective date of such Change in
Control. Executive shall also be entitled to any other rights and benefits with respect to stock-related awards, to the extent
and upon the terms provided in the employee stock option or incentive plan or any agreement or other instrument attendant thereto
pursuant to which such options or awards were granted; and

 

    	7

    

    

 

(iii) within ninety (90) days following the Date
of Termination, the Company shall pay a cash lump sum equal to the value of COBRA premiums for a period of eighteen (18) months
following the Date of Termination that may be used by Executive to pay for health insurance coverage that is substantially similar
to the coverage Executive and her eligible dependents received prior to the Date of Termination.

 

(b) Definitions. For purposes of this Paragraph 9,
the following terms shall have the following meanings:

 

“Change in Control” shall mean any of the following:

 

(a) a change in effective control consistent with
Regulation §1.409A-3(i)(5)(vi) such that any “person,” as such term is used in Sections 13(d) and 14(d) of the
Securities Exchange Act of 1934, as amended (the “Act”) (other than the Company, any of its subsidiaries, or any trustee,
fiduciary or other person or entity holding securities under any employee benefit plan or trust of the Company or any of its subsidiaries),
together with all “affiliates” and “associates” (as such terms are defined in Rule 12b-2 under the Act)
of such person, shall become the “beneficial owner” (as such term is defined in Rule 13d-3 under the Act), directly
or indirectly, of securities of the Company representing more than fifty (50) percent (50%)  of the combined voting power
of the Company’s then outstanding securities having the right to vote in an election of the Company’s Board (“Voting
Securities”) (other than as a result of an acquisition of securities directly from the Company); or

 

(b) a change in effective control consistent with
Regulation §1.409A-3(i)(5)(vi) such that persons who, as of the Commencement Date, constitute the Company’s Board (the
“Incumbent Directors”) cease for any reason, including, without limitation, as a result of a tender offer, proxy contest,
merger or similar transaction, to constitute at least a majority of the Board, provided that any person becoming a director of
the Company subsequent to the Commencement Date shall be considered an Incumbent Director if such person’s election was approved
by or such person was nominated for election by a vote of at least a majority of the Incumbent Directors; but provided further,
that any such person whose initial assumption of office is in connection with an actual or threatened election contest relating
to the election of members of the Board or other actual or threatened solicitation of proxies or consents by or on behalf of a
person other than the Board, including by reason of agreement intended to avoid or settle any such actual or threatened contest
or solicitation, shall not be considered an Incumbent Director; or

 

(c) a change in ownership consistent with Regulation
§1.409A-3(i)(5)(v) and (vii) such that the stockholders of the Company shall approve (A) any consolidation or merger
of the Company where the stockholders of the Company, immediately prior to the consolidation or merger, would not, immediately
after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Act), directly or indirectly,
shares representing in the aggregate more than fifty percent (50%) of the voting shares of the Company issuing cash or securities
in the consolidation or merger (or of its ultimate parent corporation, if any), (B) any sale, exchange or other transfer (in
one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all
of the assets of the Company or (C) any plan or proposal for the liquidation or dissolution of the Company.

 

(c) Section 280G.

 

(i) Notwithstanding any other provision of this Agreement
or any other plan, arrangement or agreement to the contrary, if any of the payments or benefits provided or to be provided by the
Company or its affiliates to the Executive or for the Executive's benefit pursuant to the terms of this Agreement or otherwise
("Covered Payments") constitute parachute payments ("Parachute Payments") within the meaning
of Section 280G of the Code and would, but for this Paragraph 9(c) be subject to the excise tax imposed under Section 4999 of the
Code (or any successor provision thereto) or any similar tax imposed by state or local law or any interest or penalties with respect
to such taxes (collectively, the "Excise Tax"), then prior to making the Covered Payments, a calculation shall
be made comparing (I) the Net Benefit (as defined below) to the Executive of the Covered Payments after payment of the Excise Tax
to (II) the Net Benefit to the Executive of the Covered Payments if the Covered Payments are limited to the extent necessary to
avoid being subject to the Excise Tax. In the event that the amount calculated under (I) above is less than the amount under (II)
above, then the Covered Payments shall be reduced to the minimum extent necessary to ensure that no portion of the Covered Payments
is subject to the Excise Tax. "Net Benefit" shall mean the present value of the Covered Payments net of all federal,
state, local, foreign income, employment and excise taxes.

 

    	8

    

    

 

(ii) Any such reduction shall be made in accordance with
Section 409A of the Code and the following:

 

(I) the Covered Payments which do not constitute nonqualified
deferred compensation subject to Section 409A of the Code shall be reduced first; and

 

(II) all other Covered Payments shall then be reduced as
follows: (A) cash payments shall be reduced before non-cash payments; and (B) payments to be made on a later payment date shall
be reduced before payments to be made on an earlier payment date.

 

(iii) Unless the Company and Executive otherwise agree
in writing, any determination required under this Paragraph 9(c) shall be made in writing in good faith by the accounting firm
that was the Company’s independent auditor immediately before a Change in Control (such firm or other party mutually agreed
in writing by the Company and Executive, the “Accountants”), which shall provide detailed supporting calculations to
the Company and the Executive as requested by the Company or the Executive. For purposes of making the calculations and determinations
required by this Paragraph 9(c), the Accountants may rely on reasonable, good faith assumptions and approximations concerning the
application of Section 280G and Section 4999 of the Code. The Accountants' determinations shall be final and binding on the Company
and the Executive. The Company shall be responsible for all fees and expenses incurred by the Accountants in connection with the
calculations required by this Paragraph 9(c).

 

10. Equity Grant/Vesting. In consideration of Executive’s
execution of, and continued compliance with, Paragraph 5(a) this Agreement, subject to Executive’s timely execution of standard
agreements evidencing the equity grants in accordance with Company’s grant policies and procedures, on the Commencement Date,
the Company will grant Executive equity awards having an aggregate value at issuance of $140,000, consisting of (i) $70,000 in
non-qualified stock options, with an exercise price set in accordance with the applicable equity plan and to equal the fair market
value as of the grant date, and which shall vest in four equal annual installments commencing with November 1, 2019 and continuing
on the next three November 1sts thereafter, and (ii) $70,000 in deferred stock awards of restricted stock units which shall vest
in four equal annual installments commencing with January 1, 2019 and continuing on the next three January 1sts thereafter.

 

11. Notice. For purposes of this Agreement, notices
and all other communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when
delivered or mailed by United States certified mail, return receipt requested, postage prepaid, addressed as follows:

 

if to the Executive:

 

At her home address as shown

in the Company’s personnel records;

 

if to the Company:

 

Harvard Bioscience, Inc.

84 October Hill Road

Holliston, MA 01746

Attention: Board of Directors of Harvard Bioscience, Inc.

 

    	9

    

    

 

with a copy to:

 

Josef B. Volman

Burns & Levinson LLP

125 Summer Street

Boston, MA 02110

 

or to such other address as either party may have furnished to the other in writing in
accordance herewith, except that notices of change of address shall be effective only upon receipt.

 

12. Successor to Company. The Company shall require
any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the
business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would
be required to perform it if no succession had taken place. Failure of the Company to obtain an assumption of this Agreement
at or prior to the effectiveness of any succession shall be a breach of this Agreement and shall constitute Good Reason if the
Executive elects to terminate employment.

 

13. Miscellaneous. No provisions of this Agreement
may be modified, waived, or discharged unless such waiver, modification, or discharge is agreed to in writing and signed by Executive
and such officer of the Company as may be specifically designated by the Board. No waiver by either party hereto of, or compliance
with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar
provisions or conditions at the same or at any prior or subsequent time. No agreements or representations, oral or otherwise,
express or implied, unless specifically referred to herein, with respect to the subject matter hereof have been made by either
party which are not set forth expressly in this Agreement. The validity, interpretation, construction, and performance of
this Agreement shall be governed by the laws of the Commonwealth of Massachusetts (without regard to principles of conflicts of
laws).

 

14. Validity. The invalidity or unenforceability
of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision of this
Agreement, which shall remain in full force and effect. The invalid portion of this Agreement, if any, shall be modified by any
court having jurisdiction to the extent necessary to render such portion enforceable.

 

15. Counterparts. This Agreement may be executed
in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the
same instrument.

 

16. Arbitration; Other Disputes. In the event
of any dispute or controversy arising under or in connection with this Agreement, the parties shall first promptly try in good
faith to settle such dispute or controversy by mediation under the applicable rules of the American Arbitration Association before
resorting to arbitration. In the event such dispute or controversy remains unresolved in whole or in part for a period of
thirty (30) days after it arises, the parties will settle any remaining dispute or controversy exclusively by final, binding,
and confidential arbitration in Boston, Massachusetts, in accordance with the rules of the American Arbitration Association then
in effect. Judgment may be entered on the arbitrator’s award in any court having jurisdiction. Notwithstanding
the above, the Company shall be entitled to seek a restraining order or injunction or other equitable relief without the need to
post a bond or provide other security in the Superior Court or business litigation session located in Suffolk County or at the
option of the Company, in the county where the Executive resides to prevent any continuation of any violation of Paragraph 4, 5,
24, 25 or 26 hereof. Furthermore, should a dispute occur concerning Executive’s mental or physical capacity as described
in Subparagraph 7(b), 7(c) or 8(b), a doctor selected by Executive and a doctor selected by the Company shall be entitled to examine
Executive. If the opinion of the Company’s doctor and Executive’s doctor conflict, the Company’s doctor
and Executive’s doctor shall together agree upon a third doctor, whose opinion shall be binding.

 

17. Third-Party Agreements and Rights. Executive
represents to the Company that Executive’s execution of this Agreement, Executive’s employment with the Company and
the performance of Executive’s proposed duties for the Company will not violate any obligations Executive may have to any
employer or other party, and Executive will not bring to the premises of the Company any copies or other tangible embodiments of
confidential information belonging to or obtained from any such previous employment or other party.

 

    	10

    

    

 

18. Litigation and Regulatory Cooperation. During
and after Executive’s employment, Executive shall reasonably cooperate with the Company in the defense or prosecution of
any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to
events or occurrences that transpired while Executive was employed by the Company so long as such cooperation does not materially
and adversely affect Executive or expose Executive to an increased probability of civil or criminal litigation. Executive’s
cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel
to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and
after Executive’s employment, Executive also shall cooperate fully with the Company in connection with any investigation
or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences
that transpired while Executive was employed by the Company. The Company shall also provide Executive with compensation on
an hourly basis at a rate equivalent to the hourly rate of the Executive’s last annual Base Salary calculated using a forty (40)
hour week over fifty-two (52) weeks for requested litigation and regulatory cooperation that occurs after her termination
of employment, and reimburse Executive for all costs and expenses incurred in connection with her performance under this Paragraph
18, including, but not limited to, reasonable attorneys’ fees and costs, if the Company in its sole discretion deems that
such compensation is reasonable and appropriate under the circumstances.

 

19. Section 409A of the Code.

 

(a) Anything in this Agreement to the contrary notwithstanding,
if at the time of the Executive’s separation from service within the meaning of Section 409A of the Code, the Company
determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the
Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement on account of the Executive’s
separation from service would be considered deferred compensation subject to the 20 percent additional tax imposed pursuant to
Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall
not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after
the Executive’s separation from service, or (B) the Executive’s death. Each payment of severance pay or other
compensation under this Agreement is a separate payment for purposes of section 409A of the Code. To the extent necessary to comply
with Section 409A, if the time period for considering and executing the Release under this Agreement spans two calendar years,
then the severance or payment will not be made or commence until the later calendar year.

 

(b) The parties intend that this Agreement will be administered
in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance
with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A
of the Code. The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary
to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and
benefits provided hereunder without additional cost to either party.

 

(c) The determination of whether and when a separation
from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).

 

(d) The Company makes no representation or warranty
and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute
deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such
Section. The parties agree to reasonably cooperate and work together to adopt amendments to this Agreement to the extent necessary
to comply with Section 409A of the Code with the intent to place Executive in the same or a substantially equivalent economic position.

 

(e) Notwithstanding anything herein to the contrary,
if Section 409A of the Code is applicable, no event shall constitute a “termination of employment” in this Agreement,
unless such event is also a “separation from service,” as that term is defined for purposes of Section 409A of the
Internal Revenue Code of 1986, as amended (“Code”), and Treasury Regulation §1.409A-3(a)(1).

 

20. Recoupment. Notwithstanding anything herein to
the contrary, Executive may be required to forfeit or repay any or all compensation received by Executive under this Agreement
pursuant to the terms of any compensation recovery, recoupment or claw-back policy that may be adopted by or applicable to the
Company with respect to or under the Dodd-Frank Wall Street Reform and Consumer Protection Act.

 

21. Survival. Notwithstanding anything to the contrary in
this Agreement, the provisions of Sections 4, 5, 6, 8 and 9 of this Agreement, and any other Sections of this Agreement that must
survive the termination of employment or expiration of the Agreement in order to effectuate the intent of the parties, shall survive
termination of Executive’s employment or expiration of the Agreement.

 

    	11

    

    

 

22. Review. Executive understands that she has the right
to consult with counsel prior to signing this Agreement and has either availed herself of that right or knowingly, willfully and
freely decided not to do so. Executive acknowledges that this Agreement was provided to Executive before or with the formal offer
of employment and more than 10 business days before the commencement of Executive’s employment.

 

23. Binding Nature of Agreement. This Agreement shall be
binding upon the Executive and upon her heirs, administrators, representatives, executors, successors and assigns, and shall inure
to the benefit of the Executive and the Company and to their heirs, administrators, representatives, executors, successors, and
assigns.

 

24. Ownership of Inventions and Works of Authorship. Executive
acknowledges that all ideas, developments, processes, discoveries, inventions, improvements, suggestions, derivations, modifications,
methods, programs, concepts, works, reports, procedures, data, documentation, writings, and applications, whether they are patentable
or not, which are made, devised, conceived, reduced to practice, developed or perfected by Executive alone or with any other person
or persons during the term of Executive’s employment by the Company which relate to or arise out of the actual and/or anticipated
business activities of the Company and which were created using any Company resources of any kind, including other employees or
by virtue of having access to and/or using Confidential Information (“Inventions”) will be the sole and exclusive property
of the Company. Executive further acknowledges that all Inventions and original works of authorship which are made by Executive
(solely or jointly with others) within the scope of and during the period of his or her employment with the Company and which are
protectable by copyright are “works made for hire,” as that term is defined in the United States Copyright Act (“Works”)
and are solely and exclusively owned by the Company. Executive agrees to disclose to the Company promptly and fully all Inventions
and Works. For all Inventions, and to the extent that any Works are not “works made for hire,” Executive hereby assigns
and agrees to assign to the Company all Executive’s right, title and interest in and to all Inventions and such Works and
all associated goodwill. Executive understands and agrees that the decision whether or not to commercialize or market any Invention
is within the Company’s sole discretion and for the Company’s sole benefit, and that no royalty will be due to Executive
as a result of the Company’s efforts to commercialize or market any such invention. Executive agrees to cooperate with and
assist the Company, or its designee, in every proper way to secure the Company’s rights in the Inventions and any copyrights,
patents, mask work rights or other intellectual property rights relating thereto in any and all countries which the Company shall
deem necessary in order to apply for and obtain such rights and in order to assign and convey to the Company, its successors, assigns,
and nominees the sole and exclusive rights, title and interest in and to such Inventions and related goodwill, and any copyrights,
patents, mask work rights or other intellectual property rights relating thereto. Executive agrees that Executive’s obligation
to execute or cause to be executed, when it is in Executive’s power to do so, any such instrument or papers shall continue
after the termination of this Agreement. If the Company is unable because of Executive’s mental or physical incapacity or
for any other reason to secure Executive’s signature to apply for or to pursue any application for any United States or foreign
patents or copyright registrations covering Inventions or original works of authorship assigned to the Company as above, then Executive
hereby irrevocably designates and appoints the Company’s duly authorized officers as Executive’s agent and attorney
in fact, to act for and on Executive’s behalf and stead to execute and file any such applications and to do all other lawfully
permitted acts to further the prosecution and issuance of letters patent or copyright registrations thereon with the same legal
force and effect as if executed by Executive. Notwithstanding the foregoing, any provision in this Agreement requiring Executive
to assign or license, or to offer to assign or license, Executive’s rights in any Development to the Company does not apply
to an invention or work of authorship that Executive developed entirely on Executive’s own time without using or referring
to the Company’s resources, equipment, supplies, facilities, or Confidential Information, except for those inventions or
works of authorship that either: (a) at the time of creation, conception or reduction to practice of the work or invention relate
to the Company’s business, or to actual or demonstrably anticipated research or development of the Company, or (b) result
from any work performed by Executive for the Company; in which cases such provisions do apply. Executive acknowledges that Executive
bears the burden of proving that an invention or work of authorship is so exempt from the assignment provisions of this Agreement.
Executive agrees to promptly disclose to the Company, in confidence, all inventions or works of authorship made solely by Executive
or jointly with others at any time during the term of Executive’s employment with the Company, for a review process under
which the Company may determine such issues as may arise, including the Company’s rights and Executive’s rights in
such inventions or works of authorship.

 

    	12

    

    

 

25. Third-Party Agreements and Rights. The Executive hereby
confirms, that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts
in any way the Executive's use or disclosure of information or the Executive's engagement in any business. The Executive represents
to the Company that the Executive's execution of this Agreement, the Executive's employment with the Company and the performance
of the Executive's proposed duties for the Company will not violate any obligations the Executive may have to any such previous
employer or other party. In the Executive's work for the; Company, the Executive will not disclose or make use of any information
in violation of any agreements with or rights of any such previous employer or other party, and the Executive will not bring to
the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any
such previous employment or third party.

 

26. Return of Company Property. Upon termination of Executive’s
employment with the Company or upon earlier demand by the Company, Executive agrees to immediately return all Company property,
including, but not limited to, any computer equipment, mobile phones, smartphones, iPhones, iPads and similar electronic devices,
office keys, credit and telephone cards, ID and access cards, and all original and duplicate copies of your work product and of
files, calendars, books, records, notes, notebooks, manuals, computer disks, diskettes, external drives, thumb drives, memory cards
and sticks, and any other digital, magnetic and other media materials Executive has in his or her possession or control belonging
to the Company, or containing Confidential Information.

[signatures on following page]

 

 

 

 

 

 

 

 

    	13

    

    

 

IN WITNESS WHEREOF, the parties have executed this Agreement
effective on the date and year first above written.

 

	 	 	HARVARD BIOSCIENCE, INC.
	 	 	 
	 	 	By: 	/s/ Jeffrey Duchemin
	 	 	 	Name: Jeffrey Duchemin
	 	 		Title: Chief Executive Officer
	 	 	 
	 	 	 
	 	 	EXECUTIVE
	 	 	 	/s/ Kam Unninayar
	 	 	 	Kam Unninayar

 

 

  

 

 

 

 

 

 

 

 

    

    

    

 

EXHIBIT A- FORM OF GENERAL RELEASE OF CLAIMS

 

This Release Agreement (the “Release Agreement”) is entered into by
Kam Unninayar (the “Executive”) in favor of Harvard Bioscience, Inc. (the “Company”). This
is the Release Agreement referenced in the Employment Agreement between the Executive and the Company dated October 18, 2018 (the
“Employment Agreement”). The consideration for the Executive’s agreement to this Release Agreement consists
of certain termination benefits as set forth in the Employment Agreement and the terms of this Release Agreement.

 

The Executive agrees as follows:

 

Release. The Executive voluntarily releases and forever discharges
the Company and each of its subsidiaries, affiliates, predecessors, successors, assigns, and current and former directors, officers,
employees, representatives, attorneys, and agents (any and all of whom or which are hereinafter referred to as “Company
Parties”), from any and all charges, complaints, claims, liabilities, obligations, promises, agreements, controversies,
damages, actions, causes of action, suits, rights, demands, costs, losses, debts and expenses (including attorney’s fees
and costs actually incurred), of any nature whatsoever, known or unknown (collectively, “Claims”) that the Executive
now has, owns or holds, or claims to have, own, or hold, or that she at any time had, owned, or held, or claimed to have had, owned,
or held against any Company Party or Parties. This general release of Claims includes, without implication of limitation, the release
of all Claims:

 

	•	 	relating to the Executive’s employment by and termination from employment with the Company; 

 

	•	 	of wrongful discharge; 

 

	•	 	of breach of contract; 
	 	 	 
	•	 	of retaliation or discrimination under federal, state or local law (including, without
        limitation, Claims of age discrimination or retaliation under the Age Discrimination in Employment Act, Claims of disability discrimination
        or retaliation under the Americans with Disabilities Act, Claims of discrimination or retaliation under Title VII of the Civil
        Rights Act of 1964 and Claims of discrimination or retaliation under Mass. Gen. Laws ch. 151B);
	 	 	 
	•	 	under the Massachusetts Weekly Payment of Wages Act, the Massachusetts Fair Employment
        Practice Act, and the Fair Labor Standards Act,

 

	•	 	under any other federal or state statute, to the fullest extent that Claims may be released; 

 

	•	 	of defamation or other torts; 

 

	•	 	of violation of public policy; 

 

	•	 	for salary, bonuses, vacation pay or any other compensation or benefits; and 

 

	•	 	for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney’s fees. 

 

1. Limitations on Release.

 

(a) Employment Agreement. Nothing in this Release Agreement
limits the Executive’s or the Company’s rights under the Employment Agreement.

 

(b) Benefit and Enforcement Rights. Nothing in this Release
Agreement is intended to release or waive the Executive’s right to COBRA, unemployment insurance benefits or any accrued
and vested retirement benefits, the right to seek enforcement of this Release Agreement or any rights referenced in this Section
of this Release Agreement.

 

(c) Indemnification. It is further understood and agreed
that the Executive’s rights to indemnification as provided in the Company’s certificate of incorporation, bylaws, each
as amended, or any indemnification agreement between the Company and the Executive (it being acknowledged and agreed by the Executive
that, as of the date of this Agreement, there are no amounts owing to the Executive pursuant to any such indemnification rights),
remain fully binding and in full effect subsequent to the execution of this Release Agreement.

 

    

    

    

 

(d) Exceptions. This Release Agreement does not prohibit
or restrict the Executive from communicating, providing relevant information to or otherwise cooperating with the EEOC or any other
governmental authority with responsibility for the administration of fair employment practices laws regarding a possible violation
of such laws or responding to any inquiry from such authority, including an inquiry about the existence of this Release Agreement
or its underlying facts; provided that such interaction with EEOC or any other governmental authority shall not result in the Executive’s
receipt of any monetary benefit or substantial equivalent thereof. This Release Agreement also does not preclude the Executive
from benefiting from classwide injunctive relief awarded in any fair employment practices case brought by any governmental agency;
provided that such relief does not result in the Executive’s receipt of any monetary benefit or substantial equivalent thereof.

 

2. No Assignment. The Executive represents that she has not
assigned to any other person or entity any Claims against any Company Party.

 

3. No Disparagement. The Executive shall not make any disparaging
statements about the Company, members of the Board of Directors, any officer of the Company or any other employee of the Company,
and the Company (acting through its officers and directors) shall not make any disparaging statements about Executive. The Executive
shall direct her immediate family not to make any disparaging statements about any of the foregoing. Any statement by a member
of her immediate family shall be deemed to be a statement by the Executive for purposes of this paragraph. The Executive shall
be considered to represent that she has complied and shall continue to comply with the nondisparagement obligations under this
paragraph from the Date of Termination (as defined in the Employment Agreement); provided that this representation shall
have no effect if this Release Agreement does not become effective. Notwithstanding the foregoing, nothing in this paragraph shall
be construed to apply to any statements made in the course of testimony in a legal proceeding or in any required written statements
in any such proceeding.

 

4. Litigation and Regulatory Cooperation. The Executive shall
reasonably cooperate with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought
in the future against or on behalf of the Company which relate to events or occurrences that transpired while Executive was employed
by the Company; provided, however, that such cooperation shall not materially and adversely affect Executive or expose Executive
to an increased probability of civil or criminal litigation. Executive’s cooperation in connection with such claims or actions
shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness
on behalf of the Company at mutually convenient times. Executive also shall cooperate fully with the Company in connection with
any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to
events or occurrences that transpired while Executive was employed by the Company. The Company shall also provide Executive with
compensation on an hourly basis at a rate equivalent to the hourly rate of the Executive’s last annual Base Salary (as defined
in the Employment Agreement) calculated using a forty (40) hour week over fifty-two (52) weeks for requested litigation
and regulatory cooperation that occurs after her termination of employment, and reimburse Executive for all costs and expenses
incurred in connection with her performance under this Section 5, including, but not limited to, reasonable attorneys’
fees and costs.

 

5. Reaffirmation of Post-Employment Restrictive Covenants.
The Executive reaffirms the restrictive covenants under the Employment Agreement to which she is subject, including without limitation,
the covenants restricting the disclosure and use of confidential information set forth in Section 4 of the Employment Agreement
and covenants regarding non-competition, non-solicitation and non-hiring set forth in Section 5 of the Employment Agreement.

 

6. Right to Consider and Revoke Release Agreement. This Release
Agreement shall be considered to have been offered to the Executive on the Termination Date as defined in the Employment Agreement.
The Executive acknowledges that she has been given the opportunity to consider this Release Agreement for a period ending twenty-one
(21) days after the Termination Date. In the event that the Executive has executed this Release Agreement within less than
twenty-one (21) days of the Termination Date, the Executive acknowledges that such decision was entirely voluntary and that
she had the opportunity to consider this Release Agreement until the end of the twenty-one (21) day period. To accept this
Release Agreement, the Executive shall deliver a signed Release Agreement to the Company’s Board of Directors within such
twenty-one (21) day period. The Executive acknowledges that for a period of seven (7) days from the date when the Executive
executes this Release Agreement (the “Revocation Period”), she shall retain the right to revoke this Release
Agreement by written notice that is received by the Board of Directors of the Company before the end of the Revocation Period.
This Release Agreement shall take effect only if it is executed by the Executive within the twenty-one (21) day period as
set forth above and if it is not revoked pursuant to the preceding sentence. If those conditions are satisfied, this Release Agreement
shall become effective and enforceable on the date immediately following the last day of the Revocation Period (the “Effective
Date”).

 

    

    

    

 

7. Consideration Owed. Executive affirms and agrees that
as of the date of this Release Agreement, you acknowledge that you will be or have been paid any and all wages (including all base
compensation and, if applicable, any and all overtime, commissions, and bonuses) to which you are or were entitled as of the date
of termination of employment, and that no other wages (including all base compensation and, if applicable, any and all incentive
compensation and bonuses) are due to Executive. Executive acknowledges that Executive is unaware of any facts or circumstances
indicating that Executive may have an outstanding claim for unpaid wages, improper deductions from pay, or any violation of the
Massachusetts Weekly Payment of Wages Act (M.G.L. c. 149, s. 148) or the Fair Labor Standards Act or any other federal, state or
local laws, rules, ordinances or regulations that are related to payment of wages.

 

8. Other Terms.

 

(a) Legal Representation; Review of Release Agreement. The
Executive acknowledges that she has been advised to discuss all aspects of this Release Agreement with her attorney. The Executive
represents that she has carefully read and fully understands all of the provisions of this Release Agreement and that she is voluntarily
entering into this Release Agreement.

 

(b) Binding Nature of Release Agreement. This Release Agreement
shall be binding upon the Executive and upon her heirs, administrators, representatives, executors, successors and assigns, and
shall inure to the benefit of the Executive and the Company and to their heirs, administrators, representatives, executors, successors,
and assigns.

 

(c) Modification of Release Agreement; Waiver. This Release
Agreement may be amended, revoked, changed, or modified only upon a written agreement executed by both the Executive and the Company.
No modification waiver of any provision of this Release Agreement will be valid unless it is in writing and signed by the party
against whom such waiver is charged. The failure of the Company to require the performance of any term or obligation of this Release
Agreement, or the waiver by the Company of any breach of this Release Agreement, shall not prevent any subsequent enforcement of
such term or obligation or be deemed a waiver of any subsequent breach.

 

(d) Severability. In the event that at any future time it
is determined by a court of competent jurisdiction that any covenant, clause, provision or term of this Release Agreement is illegal,
invalid or unenforceable, the remaining provisions and terms of this Release Agreement shall not be affected thereby and the illegal,
invalid or unenforceable term or provision shall be severed from the remainder of this Release Agreement. In the event of such
severance, the remaining covenants shall be binding and enforceable.

 

(e) Enforcement. Sections 4, 5 and 6 of this Release Agreement
shall be subject to enforcement pursuant to the same procedures that apply to a breach of Paragraphs 4 or 5 of the Employment Agreement
(as further detailed in Paragraph 16 of the Employment Agreement). Any other disputes concerning this Release Agreement shall be
subject to resolution pursuant to Section 16 of the Employment Agreement.

 

(f) Governing Law and Interpretation. This Release Agreement
shall be deemed to be made and entered into in the Commonwealth of Massachusetts, and shall in all respects be interpreted, enforced
and governed under the laws of Massachusetts, without giving effect to the conflict of laws provisions of Massachusetts law. The
language of all parts of this Release Agreement shall in all cases be construed as a whole, according to its fair meaning, and
not strictly for or against the Executive or the Company.

 

    

    

    

 

(h) Entire Agreement; Absence of Reliance. This Release
Agreement constitutes the entire agreement of the Executive concerning any subject matter of this Release Agreement and supersedes
all prior agreements between the Executive and the Company with respect to any related subject matter, except the Employment Agreement.
The Executive acknowledges that she is not relying on any promises or representations by the Company or its agents, representatives
or attorneys regarding any subject matter addressed in this Release Agreement, other than the provision of the Employment Agreement
pursuant to which Executive is to receive certain consideration in return for signing this Release Agreement and allowing it to
become effective.

 

So agreed by the Executive.

 

 

 

	 	 	 
	Executive   Kam Unninayar	 	Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}]]